Homology Medicines Inc
Change company Symbol lookup
Select an option...
FIXX Homology Medicines Inc
GNT-A Gamco Natural Resources Gold & Income Trust
AGRI AgriFORCE Growing Systems Ltd
LEN Lennar Corp
PEPL PepperLime Health Acquisition Corp
LOCL Local Bounti Corp
STVN Stevanato Group SpA
BAC Bank of America Corp
PCFBY Pacific Basin Shipping Ltd
KSCP Knightscope Inc
Go

Health Care : Biotechnology | Small Cap Blend
Company profile

Homology Medicines, Inc. is a clinical-stage genetic medicines company focused on providing treatment for rare genetic diseases. The Company’s clinical programs include HMI-102, is an investigational gene therapy candidate in clinical development for the treatment of adult patients with phenylketonuria (PKU); HMI-103, which is an investigational gene editing candidate in clinical development for the treatment of patients with PKU, and HMI-203, which is an investigational gene therapy candidate in clinical development for the treatment of patients with mucopolysaccharidosis type II (MPS II), or Hunter syndrome. Additionally, the Company is developing a gene therapy candidate, HMI-104, from its GTx-mAb platform for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH), and conducting research in other diseases, including metachromatic leukodystrophy (MLD). Its platform is designed to utilize human hematopoietic stem cell derived adeno-associated virus vectors.

Closing Price
$1.51
Day's Change
0.01 (0.67%)
Bid
--
Ask
--
B/A Size
--
Day's High
1.54
Day's Low
1.46
Volume
(Light)
Volume:
100,126

10-day average volume:
197,508
100,126

Display:

Providers:

UpdateCancel
6 providers
November 10, 2022
October 27, 2022
October 06, 2022
September 27, 2022
September 16, 2022
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Homology Medicines, Inc. (FIXX) and Encourages Long-Term FIXX Investors to Contact the Firm

EQNX::TICKER_START (NASDAQ:FIXX), EQNX::TICKER_END Kaskela Law LLC announces that it is investigating Homology Medicines, Inc. ("Homology" or the "Company") (NASDAQ: FIXX) on behalf of the Company's long-term investors. (Globe Newswire)

September 06, 2022
Homology Medicines Appoints Albert Seymour, Ph.D., Chief Executive Officer

EQNX::TICKER_START (NASDAQ:FIXX), EQNX::TICKER_END Arthur Tzianabos, Ph.D., Named Chairperson of the Board of Directors Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today the promotion of Albert Seymour, Ph.D., to...(Globe Newswire)

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.